Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 402 | 100.0 % | 482 | 100.0 % | +20.04% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 402 | 100.0 % | 482 | 100.0 % | +20.04% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joseph Belanoff
FOU | Founder | 66 | 98-05-12 |
Atabak Mokari
DFI | Director of Finance/CFO | 47 | 21-02-28 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 46 | 12-05-31 |
Hazel Hunt
CTO | Chief Tech/Sci/R&D Officer | 64 | 10-12-31 |
Jerry Pan
IRC | Investor Relations Contact | - | 21-09-30 |
Amy E. Flood
IRO | Public Communications Contact | - | 21-07-11 |
William Guyer
PRN | Corporate Officer/Principal | 56 | 21-08-15 |
Monica Tellado
PRN | Corporate Officer/Principal | 51 | Oct. 31 |
Sean Maduck
PRN | Corporate Officer/Principal | 47 | 11-12-31 |
Gary Robb
SEC | Corporate Secretary | 61 | 11-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Belanoff
FOU | Founder | 66 | 98-05-12 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-03-11 |
George Baker
BRD | Director/Board Member | 81 | 98-12-31 |
James Wilson
CHM | Chairman | 80 | 98-12-31 |
David Mahoney
BRD | Director/Board Member | 69 | 04-06-30 |
Daniel Swisher
BRD | Director/Board Member | 61 | 15-06-17 |
Kimberly Park
BRD | Director/Board Member | 60 | 19-09-17 |
Gillian Cannon
BRD | Director/Board Member | 60 | 20-11-22 |
Joshua Murray
BRD | Director/Board Member | 40 | 21-06-08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 134,775,166 | 91,987,550 ( 68.25 %) | 30,938,000 ( 22.96 %) | 68.25 % |
Company contact information
Corcept Therapeutics, Inc.
149 Commonwealth Drive
94025, Menlo Park
+650 327 3270
http://www.corcept.comSector
1st Jan change | Capi. | |
---|---|---|
+25.83% | 653B | |
+27.00% | 556B | |
-6.76% | 354B | |
+20.34% | 331B | |
+3.00% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.26% | 144B |